A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.

被引：0
|
作者：
Kobrossy, B
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页码：343S / 343S
页数：1
相关论文
共 50 条
  • [41] Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer A Phase II Study
    Safran, Howard
    Miner, Thomas
    Bahary, Nathan
    Whiting, Sam
    Lopez, Charles D.
    Sun, Weijing
    Charpentier, Kevin
    Shipley, Joshua
    Anderson, Elliot
    McNulty, Brendan
    Schumacher, Andrew
    Clark, Alessandra
    Vakharia, Jamsheed
    Kennedy, Teresa
    Sio, Terence
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (01): : 50 - 52
  • [42] Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study
    Safran, H.
    Miner, T.
    Bahary, N.
    Whiting, S.
    Lopez, C.
    Sun, W.
    Charpentier, K.
    Charpentier, K.
    Shipley, J.
    Anderson, E.
    McNulty, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A phase II trial of pharmacological ascorbate, gemcitabine, and nabpaclitaxel for metastatic pancreatic cancer.
    Kasi, Pashtoon Murtaza
    Bodeker, Kellie
    Berg, Daniel James
    Chandrasekharan, Chandrikha
    Sharif, Saima
    Smith, Brian J.
    Vollstedt, Sandy
    Brown, Heather
    Chandler, Meghan
    Cullen, Joseph J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] A Phase I/II trial of weekly gemcitabine with celecoxib and thalidomide for patients with advanced pancreatic cancer.
    Densmore, JJ
    Fox, JR
    Kannarkat, G
    Morgan, JK
    Petroni, G
    Blount, T
    Sullivan, K
    Williams, ME
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 367S - 367S
  • [45] Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
    Tempero, M
    Plunkett, W
    van Haperen, VR
    Hainsworth, J
    Hochster, H
    Lenzi, R
    Abbruzzese, J
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3402 - 3408
  • [46] PHASE II STUDY OF FIXED-DOSE RATE (FDR) GEMCITABINE AS A RADIOSENSITIZER FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Fabi, A.
    Mirri, A. M.
    Metro, G.
    Felici, A.
    Vidiri, A.
    Pace, A.
    Carosi, M. A.
    Cognetti, F.
    Occhipinti, E. M.
    Carapella, C. M.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1123 - 1123
  • [47] Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma
    Carneiro, Benedito A.
    Brand, Randall E.
    Fine, Elita
    Knop, Richard H.
    Khandekar, Janardan D.
    Uhlig, William
    Locker, Gershon Y.
    CANCER INVESTIGATION, 2007, 25 (05) : 366 - 371
  • [48] Phase II study of induction chemotherapy with fixed dose rate (FDR) gemcitabine and cisplatin followed by concurrent chemoradiation with capecitabine for locally advanced pancreatic cancer (LAPC)
    Kim, J.
    Im, S.
    Park, H.
    Chie, E.
    Hwang, J.
    Kim, J.
    Kim, T.
    Bang, Y.
    Ha, S.
    Yoon, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] GEMCITABINE (GEM) PLUS CELECOXIB IN ADVANCED PANCREATIC CANCER: A PHASE II STUDY
    Valcamonico, F.
    Ferrari, V. D.
    Simoncini, E.
    Amoroso, V.
    Vassalli, L.
    Rangoni, G.
    Grisanti, S.
    Marpicati, P.
    Marini, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [50] Phase II study of gemcitabine plus cisplatin in metastatic breast cancer
    Fuentes, Homero
    Calderillo, German
    Alexander, Francisco
    Ramirez, Marcelino
    Avila, Enrique
    Perez, Leonel
    Aguirre, Guillermo
    Onate-Ocana, Luis F.
    Gallardo, Dolores
    Otero, Jorge
    ANTI-CANCER DRUGS, 2006, 17 (05) : 565 - 570
12345